Bimzelx (bimekizumab-bkzx) — Medica

Plaque psoriasis

Initial criteria

Patient has tried and had an inadequate response to, or is intolerant to, at least one traditional systemic agent for psoriasis (e.g., methotrexate, cyclosporine, acitretin, or phototherapy); OR patient has a contraindication to methotrexate, as determined by the prescriber
According to the prescriber, the patient has been evaluated for risks of suicidal ideation or behavior versus benefits of therapy
According to the prescriber, the patient does not have moderately severe to severe depression
According to the prescriber, within the past 5 years, the patient does not have a history of suicidal ideation or suicidal behavior
The medication is prescribed by or in consultation with a dermatologist

Patient has been established on therapy for at least 3 months
According to the prescriber, the patient has been evaluated for risks of suicidal ideation or behavior versus benefits of therapy
According to the prescriber, the patient does not have moderately severe to severe depression
According to the prescriber, the patient does not have suicidal ideation or suicidal behavior
Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Bimzelx) in at least one of the following: estimated body surface area, erythema, induration/thickness, and/or scale of areas affected by psoriasis
Compared with baseline (prior to receiving Bimzelx), patient experienced an improvement in at least one symptom such as decreased pain, itching, and/or burning

initial 6 months, reauthorization 1 year